New drug target may help prevent, reverse obesity: Study

Image
Press Trust of India Washington
Last Updated : Jan 15 2020 | 3:55 PM IST

Researchers have found a critical target in mice, which can prevent and reverse weight gain without side effects, an advance which may lead to novel therapies to combat obesity.

According to the study, published in the International Journal of Obesity, a receptor found in almost all cells called AHR, known to combat exposures to environmental chemicals, plays a major role in the body's metabolism.

"We carried out experiments showing that when a drug named NF and known to block the AHR, was added to a high-fat diet, mice did not become any fatter than mice on a low-fat control diet," said Craig Tomlinson, study co-author from the Dartmouth-Hitchcock's Norris Cotton Cancer Center in the US.

"Mice on the high-fat diet with no NF became very obese within the same time span. No ill effects were observed from the drug," Tomlinson said.

In the study, the scientists allowed the mice to become obese on a high-fat diet, and then switched half of the rodents to a high-fat diet containing the AHR blocker NF.

Over the following weeks, the mice which were switched to the diet containing NF dropped to the same body weight as those on the low-fat diet.

"The remaining mice on the high-fat diet became obese. Again, no ill effects were observed," Tomlinson said.

According to the scientists, the AHR regulates key genes involved in fat metabolism.

The current study revealed that in liver and fat cells, the AHR, when blocked by NF, fails to induce several key genes required for fat storage and synthesis.

Based on this finding, the researchers concluded that the prevention and reversal of obesity from blocking the activity of the AHR is due to key genes regulated by the AHR which are involved in fat metabolism.

"Few to no studies have shown that obesity can be reversed by a drug treatment. It is even rarer to know the underlying cellular mechanism," Tomlinson said.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 15 2020 | 3:55 PM IST

Next Story